AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Celsius Therapeutics Announces Executive Leadership Team Appointments

May 22, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 22, 2019--

Celsius Therapeutics, a company translating single-cell genomic insights into precision therapeutics for patients with autoimmune diseases and cancer, today announced its first key leadership appointments. Greg Ryslik, Ph.D., has joined as chief data officer, and Michael Boretti, Ph.D., has joined as chief business officer.

“Over the past year, we have been building our team and assembling an integrated, industrial-scale platform that combines single-cell genomics, machine learning, deep biology and drug discovery, which has enabled Celsius to advance its understanding of the specific cells and genetic drivers that could play a key role in autoimmune diseases and cancer,” said Alexis Borisy, chairman of Celsius. “Greg’s demonstrated leadership in applying machine learning to extract unique insights across a spectrum of large, complex datasets will add more power to our target and drug discovery engine, while Mike’s range of experiences, including leading corporate strategy development and partnership formation, will be instrumental to maximizing the value and impact of our platform and pipeline.”

Dr. Ryslik is a statistician, data scientist and artificial intelligence researcher with experience building and leading data initiatives in companies ranging across the biotech, autotech, healthtech and fintech domains. Prior to Celsius, he was vice president of data science at Mindstrong Health, a healthcare company transforming mental health treatment through measurement science and artificial intelligence. Previously, Dr. Ryslik was the senior director and head of data science at Faraday Future, an electric vehicle startup in Los Angeles as well as the leader of the service data science group at Tesla Motors in Palo Alto. Earlier in his career, he performed machine learning research and nonclinical biostatistics research at Genentech. Concurrently, Dr. Ryslik holds an adjunct assistant professor position at Pennsylvania State University and has lectured on statistics for artificial intelligence, machine learning at Stanford University Continuing Studies. He holds a Ph.D. from Yale University in biostatistics, where he researched oncogenic mutation clustering embedded within protein structure. He also holds a master’s degree in statistics from Columbia University and an undergraduate degree in mathematics, computer science and finance from Rutgers University.

Dr. Boretti brings to Celsius Therapeutics nearly 15 years of experience in the biotechnology industry, including leadership roles encompassing business development, strategic planning, and program and alliance management. He has a strong track record of planning, negotiating and implementing strategic alliances across a wide range of collaboration structures. He joins Celsius from Epizyme, where he was vice president of business development and responsible for the formation new partnerships, including key collaborations with Boehringer Ingelheim and Roche, while also overseeing management of numerous other strategic alliances. Prior to Epizyme, Dr. Boretti worked in roles of increasing responsibility at AVEO Oncology, most recently serving as vice president, corporate development and alliance management, where he drove the formation of partnerships around many of AVEO’s clinical- and discovery-stage programs, including significant transactions with Novartis, Janssen and Astellas. Prior to AVEO, Dr. Boretti was a consultant in the life sciences practice at L.E.K. Consulting, a global strategic consulting firm. He holds an undergraduate degree in engineering science from the University of Virginia and a Ph.D. in bioengineering from the University of Pennsylvania.

About Celsius Therapeutics

Celsius Therapeutics is charting a new course of target and drug discovery by applying a systematic approach to single-cell sequencing of patient tissue, combining massive datasets, complex algorithms, and machine learning to discover first-in-class precision therapies with a transformative impact on the lives of patients with autoimmune diseases and cancer. Celsius was launched in 2018, is backed by Third Rock Ventures and GV (formerly Google Ventures), and is based in Cambridge, Mass. For more information, please visit www.celsiustx.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190522005206/en/

CONTACT: Katie Engleman

1AB

katie@1abmedia.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL

SOURCE: Celsius Therapeutics

Copyright Business Wire 2019.

PUB: 05/22/2019 08:30 AM/DISC: 05/22/2019 08:31 AM

http://www.businesswire.com/news/home/20190522005206/en

All contents © copyright 2019 The Associated Press.All rights reserved.